Dry Eye
Conditions
Interventions
Group DQS:The patient was treated with 3 % diquafosol sodium eye drops, 6 times / day, for three months.
Group Control:Saline eye drops are given.
Sponsors
Chongqing Aier Children's Eye Hospital
Eligibility
Sex/Gender
All
Age
8 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1.Aged between 8 and 18 years old ; 2.The degree of myopia ranged from - 1.00 D to - 6.00 D, the degree of astigmatism ranged from regular astigmatism < - 1.75 D or irregular astigmatism < - 0.75 D, and the corneal curvature ranged from 39.00 D to 48.00 D ; 3.First fitting OK mirror or compound patients ; 4.Light to moderate dry eye or potential risk of dry eye, non-invasive tear break-up time ( NIBUT.< 10 s and / or non-invasive tear meniscus height ( TMH.< 0.20 mm ; 5.Minors should voluntarily participate in this study under the supervision of their parents, and the guardian should sign a written informed consent form and follow up regularly according to the doctor 's prescription for rational drug use.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of allergies to any component of the drug or test ( such as diquafosol sodium, fluorescein.scheduled for use in the study. 2.Use other dry eye treatment drugs such as 3 % diquafosol sodium eye drops within 2 weeks before enrollment, and drugs that may cause dry eye or affect vision and corneal curvature. 3.Corneal endothelial cell density less than 2000 / mm2. 4.The researchers determined the use of drugs that affect or may affect the wearing of orthokeratology lenses and may change normal eye physiology. 5.Active corneal infection, or other acute and chronic inflammation of the anterior segment. 6.corneal abnormalities ; corneal epithelium obvious fluorescence staining ; have received corneal surgery, or have a history of corneal trauma ; active keratitis ( such as corneal infection, etc. ), corneal hypoesthesia. 7.Other eye diseases : such as dacryocystitis, eyelid diseases and eyelid abnormalities, abnormal intraocular pressure and glaucoma. 8.Patients with systemic diseases caused by low immune function, or have an impact on corneal shaping ( such as acute and chronic sinusitis, diabetes, Down 's syndrome, rheumatoid arthritis, psychiatric patients, etc. ). 9.Pregnant women, lactating or recently planning to get pregnant. 10.Patients who had participated or were participating in other clinical trials within 1 month ; 11.The researchers judged that it was not suitable for patients to enter this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DEQ-5 score;IOP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-contact tear film break-up time;Non-contact River of Tears height;Non-contact tear secretion;Non-contact corneal conjunctival staining score;Axial length;Vision; | — |
Countries
China
Contacts
Public ContactHe Yongchuan
Chongqing Aier Children's Eye Hospital
Outcome results
None listed